RxDoctor Payments Data

Kerry Harris

Family · Las Cruces, NMNPI 1164738399

Payments from drug & device makers

$3,116in general payments, 2019–2025

Across 155 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$873
  • Johnson & Johnson$665
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$398
  • Pfizer$279
  • Takeda Pharmaceuticals U.S.A., Inc.$236
  • Phathom Pharmaceuticals, Inc.$228
  • plus $437 from 7 others

What the payments were for

  • Food & beverage$2,93094%
  • Education$1866%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,116 in reported general payments places this provider in the 90th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$28,550
Medicare patients
248
Services billed
288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin17$59,095
LinzessLinaclotide45$37,797
SymproicNaldemedine Tosylate12$5,595
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg190$3,810
Dicyclomine Hcl84$2,827
Famotidine94$1,841
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,796
Pantoprazole Sodium134$1,478
Omeprazole53$1,225
Lactulose42$829
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl35$773
Ondansetron Hcl24$767
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl24$592
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine13$388
Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg18$263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$398$59,09517 claims
AbbVieLinzess$873$37,79745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,080 family providers in New Mexico.

Other family in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →